Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTO Aptose Biosciences		$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	650,294 shs
EVAX Evaxion A/S	$3.06 +3.9%	$2.64	$1.20 ▼ $17.75	$4.29M	0.13	965,786 shs	39,937 shs
IKT Inhibikase Therapeutics	$1.69 +0.3%	$1.77	$1.12 ▼ $4.20	$125.27M	0.9	191,536 shs	16,537 shs
SRZN Surrozen	$11.54 +0.3%	$9.39	$5.90 ▼ $18.17	$98.78M	0.6	19,591 shs	33,243 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	-88.25%
EVAX Evaxion A/S	-2.96%	-2.96%	+14.79%	+57.75%	-81.68%
IKT Inhibikase Therapeutics	-1.18%	-1.75%	-10.64%	-8.70%	+19.15%
SRZN Surrozen	+3.14%	+14.31%	+32.18%	+41.28%	+57.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APTO Aptose Biosciences	1.1058 of 5 stars	3.8	0.0	0.0	0.0	0.0
EVAX Evaxion A/S	2.4054 of 5 stars	3.5	2.0	2.1	1.7	0.6
IKT Inhibikase Therapeutics	2.0637 of 5 stars	3.3	2.0	2.2	0.0	1.3
SRZN Surrozen	2.7439 of 5 stars	3.5	2.0	2.9	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APTO Aptose Biosciences	3.50	Strong Buy	$6.00	∞ Upside
EVAX Evaxion A/S	3.00	Buy	$10.00	226.37% Upside
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	285.76% Upside
SRZN Surrozen	3.00	Buy	$38.50	233.62% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
EVAX Evaxion A/S	$3.34M	1.28	N/A	N/A	$4.44 per share	0.69
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
SRZN Surrozen	$10.65M	9.28	N/A	N/A	$5.50 per share	2.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APTO Aptose Biosciences	-$51.21M	-$89.19	N/A	N/A	N/A	N/A	-5,683.22%	-300.44%	N/A
EVAX Evaxion A/S	-$10.57M	-$1.32	N/A	N/A	N/A	-316.03%	-319.52%	-63.56%	10/30/2025 (Estimated)
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
SRZN Surrozen	-$63.56M	-$14.42	N/A	N/A	N/A	-274.42%	-545.43%	-64.40%	11/5/2025 (Estimated)

Latest EVAX, APTO, SRZN, and IKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	EVAX Evaxion A/S	-$0.50	-$0.76	-$0.26	-$0.76	N/A	$0.04 million
8/8/2025	Q2 2025	SRZN Surrozen	-$1.23	-$1.14	+$0.09	$2.55	N/A	$0.98 million
5/27/2025	Q1 2025	EVAX Evaxion A/S	-$0.65	-$0.29	+$0.36	-$0.29	$0.06 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
EVAX Evaxion A/S	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APTO Aptose Biosciences	N/A	1.05	1.05
EVAX Evaxion A/S	1.73	3.42	2.01
IKT Inhibikase Therapeutics	N/A	0.85	0.85
SRZN Surrozen	N/A	16.41	16.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APTO Aptose Biosciences	26.62%
EVAX Evaxion A/S	11.04%
IKT Inhibikase Therapeutics	3.81%
SRZN Surrozen	66.57%

Insider Ownership

Company	Insider Ownership
APTO Aptose Biosciences	1.33%
EVAX Evaxion A/S	41.64%
IKT Inhibikase Therapeutics	7.30%
SRZN Surrozen	45.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APTO Aptose Biosciences	31	2.14 million	63.45 million	No Data
EVAX Evaxion A/S	60	1.40 million	819,000	No Data
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
SRZN Surrozen	80	8.56 million	4.69 million	Not Optionable

EVAX, APTO, SRZN, and IKT Headlines

Recent News About These Companies

HC Wainwright Issues Positive Forecast for Surrozen Earnings

August 16, 2025 | marketbeat.com

HC Wainwright Issues Positive Estimate for Surrozen Earnings

August 16, 2025 | americanbankingnews.com

Surrozen (NASDAQ:SRZN) Issues Earnings Results

August 11, 2025 | marketbeat.com

Vivo Capital LLC Takes Position in Surrozen, Inc. (NASDAQ:SRZN)

August 9, 2025 | marketbeat.com

Surrozen (NASDAQ:SRZN) Stock Price Down 12.8% - Should You Sell?

August 9, 2025 | marketbeat.com

Surrozen’s Q2 2025: Progress in Eye Disease Therapies

August 8, 2025 | tipranks.com

Surrozen Reports Q2 Profit on Gains

August 8, 2025 | fool.com

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

August 8, 2025 | globenewswire.com

Surrozen to Present at Upcoming Healthcare Investor Conference

August 6, 2025 | globenewswire.com

Surrozen (SRZN) Projected to Post Earnings on Monday

August 5, 2025 | marketbeat.com

We Think Surrozen (NASDAQ:SRZN) Can Afford To Drive Business Growth

July 1, 2025 | finance.yahoo.com

Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround

May 16, 2025 | zacks.com

Surrozen secures patent for tissue repair technology

May 15, 2025 | investing.com

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

May 14, 2025 | globenewswire.com

Surrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 10, 2025 | finanznachrichten.de

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025 | globenewswire.com

Surrozen files to sell 5.21M shares of common stock for holders

April 25, 2025 | markets.businessinsider.com

Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year

April 2, 2025 | markets.businessinsider.com

Insiders Are Loving These 5 Tech and Biotech Stocks

April 2, 2025 | 247wallst.com

Surrozen Focuses on Ophthalmology Amid Financial Challenges

April 1, 2025 | tipranks.com

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

March 31, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVAX, APTO, SRZN, and IKT Company Descriptions

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Evaxion A/S NASDAQ:EVAX

$3.06 +0.11 (+3.86%)

As of 03:04 PM Eastern

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Inhibikase Therapeutics NYSE:IKT

$1.68 +0.01 (+0.30%)

As of 03:04 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Surrozen NASDAQ:SRZN

$11.54 +0.04 (+0.35%)

As of 03:06 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time